With Cysview Blue Light technology, physicians at East Jefferson General Hospital (EJGH) can detect tumors related to bladder cancer more effectively than ever before.
In Louisiana and Mississippi, only East Jefferson General Hospital has this technology. Having Blue Light puts EJGH in exclusive company with only 100 hospitals in the United States, including leading cancer centers like MD Anderson, UAB, The Cleveland Clinic, Johns Hopkins, and the medical centers at both Vanderbilt and Ohio State University.
Cysview (hexaminolevulinate HCI) is an optical imaging agent indicated for use in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder among patients suspected or known to have lesions on the basis of a prior cystoscopy. Cysview enters the mucosal cells and acts as a precursor to porphyrins, which selectively accumulate in rapidly proliferating cells (e.g., tumors). During a cystoscopy, blue light causes the porphyrin within tumors to fluoresce a pink color, which contrasts with normal mucosa.
Trials in the United States, Canada, and Europe led to Cysview being the only FDA approved technology that allows greater detection, better patient management decisions, and improved tumor resection. It was effective in more than 1,800 known or suspected bladder cancer cases. For those with bladder cancer, this represents a safer, more accurate and effective way of identifying and removing tumors.